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The Variable Presentations of Anaplastic Spindle Cell
Squamous Carcinoma Associated with Tall Cell Variant
of Papillary Thyroid Carcinoma
Pallavi P. Gopal,1 Kathleen T. Montone,1 Zubair Baloch,1 Madalina Tuluc,2 and Virginia LiVolsi1
Background: In 1976, Hawk and Hazard described the tall cell variant (TCV) of papillary thyroid carcinoma
(PTC). While the lesions they described had cytologic features of papillary carcinoma, they showed more
aggressive behavior with a greater propensity for extrathyroid extension and lymphovascular invasion than
classic PTC. In 1991, Bronner and LiVolsi described a series of patients with TCV that progressed to spindle cell
squamous carcinoma (SCSC), a unique form of anaplastic thyroid carcinoma. This study describes the variable
clinical and pathologic presentations in 31 patients with anaplastic SCSC arising in association with TCV.
Methods: The surgical pathology archives as well as the personal consultation files of one of the authors (V.A.L.)
were reviewed to retrieve cases of SCSC arising in association with TCV. The available clinical as well as
pathologic information on all patients was reviewed.
Results: A total of 31 patients with SCSC arising in association with TCV were retrieved from our files. The
average age at primary presentation was 67 (range 32–92) with a female-to-male ratio of 2:1. Three clinical
scenarios for SCSC associated with TCV were identified. These were type I, consisting of TCV with SCSC at the
time of presentation (18 patients); type II, consisting of SCSC arising as a recurrence in patients with a known
history of TCV (5 patients); and type III, consisting of SCSC presenting as a primary laryngeal squamous cell
carcinoma in a patient with or without a known history of TCV (8 patients). The type III cases were of most
concern since they often were confused with primary laryngeal squamous cell carcinoma and most often were
diagnosed after laryngectomy.
Conclusions: SCSC of the thyroid is almost exclusively associated with TCV and can have variable clinical
presentations. SCSC is most commonly seen associated with a primary diagnosis of TCV. SCSC may be seen,
however, in patients with recurrent PTC and most importantly may present in a fashion similar to primary
laryngeal SCSC. Therefore, caution should be exercised in evaluating laryngeal squamous lesions in patients
with known history of TCV and without known risks factors for head and neck carcinogenesis.
Introduction
The tall cell variant (TCV) of papillary thyroid carci-noma (PTC), first described by Hawk and Hazard in
1976, has been defined as a tumor composed of >50% cells
whose heights are at least two or three times their widths and
have nuclear features of PTC (1,2). TCV tends to occur in older
patients, forms larger and bulkier tumor masses, is more
likely to show extrathyroidal extension, and shows more ag-
gressive behavior, suggesting that TCV has a pathobiology
distinct from classic PTC (1,3).
In addition, Bronner and LiVolsi and others have noted that
some cases of TCV progress to spindle cell squamous carci-
noma (SCSC), an unusual form of anaplastic carcinoma, with
both spindle cell elements and squamous islands with focal
keratinization (4,5). We now describe the variable clinical and
pathologic presentations of 31 patients with SCSC arising in
association with TCV. In the most common clinical scenario
(type I), both TCV and SCSC components are present in the
initial resection. In the second scenario (type II), SCSC arises
as a recurrence in a patient with a known history of TCV. In
the third clinical presentation, SCSC presents as a mimic of
primary laryngeal squamous cell carcinoma in a patient who
may or may not have a known history of TCV. These data
indicate that a diagnosis of TCV is clinically relevant
for pathologic evaluation of both the initial resection and
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recurrences, which may contain anaplastic SCSC. This is an
important consideration in the differential diagnosis because
SCSC may occur as a primary tumor in the oropharyngeal
region. Further, patients with a history of TCV PTC who
present with a presumed primary laryngeal squamous cell
carcinoma should be evaluated for the possibility of a recur-
rence of TCV with transformation to SCSC, particularly if the
patient does not have other risk factors for head and neck
carcinogenesis.
Materials and Methods
This study was approved by the University of Pennsylva-
nia Institutional Review Board. The cases were selected from
the Surgical Pathology files from the Hospital of the Uni-
versity of Pennsylvania (20 cases) and the consultation files of
one of the authors (V.A.L.; 11 cases). Clinical information was
obtained through chart review, and the available pathologic
history was reviewed for each case. Hematoxylin and eosin-
stained sections were reviewed. In some of the type II and
type III cases, the histology of the primary tumor and a few of
the recurrences (type II cases only; see below) were not
available for review since many of these specimens were at
other institutions and from several years ago. In some of the
cases, immunostains were available; these stains included
cytokeratins, thyroid transcription factor 1 (TTF-1), and thy-
roglobulin.
Results
In all cases, the tall cell papillary component displayed long,
well-formed papillae with fibrovascular cores lined by tall
columnar cells with pink cytoplasm, in which the cell height
was two to three times the cell width (Fig. 1A). In addition, the
cells had typical nuclei of papillary carcinoma, with enlarged
oval and overlapping nuclei showing central clearing and
ground glass chromatin. Nuclear grooves and multiple in-
tranuclear inclusions, which give rise to the characteristic
‘‘soap bubble’’ intranuclear inclusions characteristic of TCV on
cytologic preparations (6), were also observed. The SCSC an-
aplastic component showed spindle cells as well as solid nests
and infiltrating islands of moderately differentiated squa-
mous cell carcinoma, some of which had bland cytology
(Fig. 1B). Other areas showed anaplastic spindle cells with a
high nuclear:cytoplasmic ratio, pleomorphic, hyperchromatic
nuclei with irregular contours, and prominent nucleoli.
The clinical and pathologic findings are summarized in
Tables 1–3. The average age at presentationwas 67 (range 32–92)
with a female-to-male ratio of 2:1. Patients found to have
SCSC associated with TCV presented in three clinical and
pathologic scenarios. Clinically, the majority of patients sim-
ply presentedwith a thyroidmass (18 patients); histologically,
these cases were characterized by a mixture of TCV PTC and
SCSC present concurrently in the thyroidectomy specimen
(type I). Both tumor morphologies were intimately admixed,
with areas of transition from TCV PTC to the spindled and
squamous appearance of the anaplastic component. The
transition zone was notable for areas of hemorrhage, and the
squamous cells, some of which appear bland, merge with
more hyperchromatic, pleomorphic nuclei of the anaplastic
squamous and spindled cells. Extrathyroidal extension and
lymphovascular invasion were seen in 14 and 8 (14/18 and
8/18), respectively, of the type I cases.
The tumors in the second group of cases (5 patients; type II)
initially demonstrated TCV PTC in the thyroid resection, but
the anaplastic SCSC developed only in recurrences or me-
tastases, months to years later. In both cases 7 and 9 (Table 2),
the transformation to SCSC occurred longer than 15 years
after the diagnosis of TCV. The site of recurrence with SCSC
transformation was most often in neck lymph nodes. Excision
of these enlarged lymph nodes demonstrated metastatic TCV
PTC with solid squamoid nests and pleomorphic spindled
areas, consistent with SCSC transformation. In addition to
anaplastic transformation in neck lymph nodes, one patient
also had spindle-cell anaplastic carcinoma in an en-
dobronchial mass (Case 28, Table 2). Metastatic TCV PTC in
multiple pulmonary nodules was noted in another case;
however, SCSC transformation was not seen in the lung
wedge resection (Case 9, Table 2).
In the third clinical scenario (type III), eight patients pre-
sented with a laryngeal mass (Fig. 2), and in four cases had a
biopsy showing invasive squamous cell carcinoma before
laryngectomy. The smoking history was only available for
two of these patients (Cases 15 and 29). Whereas one of the
patients (Case 15) had a 20 pack-year smoking history at the
time of presentation with the laryngeal mass, the other patient
(Case 29) was a life-long nonsmoker and had no obvious risk
factors for head and neck carcinogenesis. Five of the eight
patients had a prior history of PTC, and three of these five
patients were known to have had TCV. In all cases, however,
evaluation of the laryngectomy specimen revealed anaplastic
SCSC arising in association with TCV PTC. The lack of an
associated in situ squamous carcinoma or dysplasia in the
laryngeal mucosa argued against a primary laryngeal squa-
mous cell carcinoma in these cases. In addition, the intimate
association of the TCV and SCSC components, with transi-
tions between PTC to SCSC, strongly suggests that both
morphologies are components of one tumor, rather than from
the collision of two tumors. Although not routinely available
before 2000, TTF-1 immunoreactivity is also helpful for dis-
tinguishing between these possibilities. The expression of
TTF-1 by the squamous anaplastic component is strong evi-
dence that the squamous cells are derived from follicular cells
(Fig. 3) and are less likely to represent a concurrent or meta-
static squamous carcinoma colliding with PTC.
Discussion
TCV of PTC, first described in 1976, is distinguished from
other types of PTC by its tall columnar cell shape, with a
height:width ratio of 2–3:1, and abundant eosinophilic or
oxyphilic cytoplasm (1,2). The accurate classification of TCV is
clinically relevant, since these tumors tend to behave more
aggressively (7,8), and TCVmay transform to SCSC anaplastic
carcinoma (4,5). We now describe the variable clinical pre-
sentations of 31 patients with anaplastic SCSC arising from
TCV PTC and the clinical and pathologic considerations for
diagnosis of these unusual tumors. Based on histologic ex-
amination, each case was classified into one of three clinical
presentations: type I, in which TCV and SCSC are both iden-
tified in the initial resection (18 patients); type II, in which
SCSC arises as a recurrence/metastasis in patients with a
known history of TCV (5 patients); and type III, inwhich SCSC
presents as a primary laryngeal squamous cell carcinoma in a
patient with or without a known history of TCV (8 patients).
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Most commonly, patients with SCSC arising from TCV
present with both tumor morphologies in close apposition in
the initial thyroid resection specimen (type I) and present with
a clinical thyroid mass. In contrast, the type II cases had a
history of TCV or prior thyroidectomywith TCVPTC;months
to years later, however, these patients presented with recur-
rences, most often in cervical lymph nodes, that showed
metastatic TCV with dedifferentiation and transformation to
SCSC. In both the type I and II cases, the histology demon-
strates areas of transition from the well differentiated tall cell
morphology, to more poorly differentiated, and spindle and
squamous anaplastic morphology, and this intimate rela-
tionship leaves little diagnostic question that the SCSC arose
in association with TCV PTC.
The type III cases presented very differently, with a
laryngeal mass; four of eight patients had a biopsy diagnosed
as invasive squamous cell carcinoma or poorly differentiated
malignant neoplasm. These patients were presumed clinically
to have a primary laryngeal squamous cell carcinoma. Only
five of these patients had a history of PTC (three of who were
found to have TCV PTC). In these cases, the clinical presen-
tation of a laryngeal mass and the length of time (ranging
from 2 to 15 years) from the apparently cured PTC led to the
assumption that the new mass was a primary squamous
carcinoma of the larynx. Hence, all type III patients under-
went layrngectomy. However, histologic evaluation of the
laryngectomy specimens showed anaplastic SCSC admixed
with areas of TCV of papillary carcinoma.
The differential diagnosis includes a collision of a primary
laryngeal SCSC with a recurrent PTC, or SCSC arising in as-
sociation with TCV PTC. In all cases, the lack of an associated
in situ squamous carcinoma or dysplasia argues against a
primary laryngeal squamous cell carcinoma. In addition, the
intimate association of the TCV and SCSC components, with
transitions between TCV PTC to SCSC, strongly suggests that
both components arose from one tumor, rather than from the
collision of two tumors. TTF-1 positivity in the SCSC com-
ponent in more recently diagnosed cases helps determine the
primary origin of these tumors from the pre-existing TCV.
(TTF-1 immunohistochemistry was not performed in all cases,
as tissue blocks were not always available [consult cases], and
in cases before 2000, TTF-1 immunostaining was not routinely
available.)
FIG. 1. (A) Tall cell variant pap-
illary thyroid carcinoma is charac-
terized by well-formed papillae
lined by tall columnar cells with
pink cytoplasm and cell height two
to three times the cell width. The
cells also have typical nuclei of
papillary carcinoma, with enlarged
oval and overlapping nuclei
showing central clearing, ground
glass chromatin, and occasional
nuclear grooves. (B) The transition
zone between tall cell variant and
the anaplastic component shows
solid areas of squamous cells, some
of which have bland cytology.
FIG. 2. Gross photograph of laryngectomy specimen from
Case 17, bisected to reveal a poorly circumscribed solid tu-
mor mass involving the infraglottic space.
FIG. 3. TTF-1 immunostaining of the squamous anaplastic
component strongly supports the thyroid follicular origin of
these cells, rather than a concurrent primary squamous car-
cinoma of the larynx (collision tumor). TTF-1, thyroid tran-
scription factor 1.
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Table 1. Summary of Clinical and Pathologic Findings in Anaplastic Spindle Cell
Squamous Carcinoma Arising in Tall Cell Variant (Type 1)
Case Age/gender Summary of clinical and pathologic findings
1 59/M History of astrocytoma status postresection 10 years before presentation and hemi-thyroidectomy
5 years before presentation (by history said to be benign lesion); presents with 1 month of stridor,
dysphagia, hoarseness, and large left thyroid mass with compression of trachea.
Pathology: Anaplastic SCSC arising from TCV PTC, with invasion into perithyroidal soft tissue,
parathyroid, and skeletal muscle; þLVI, þPNI.
2 59/F Former smoker with emphysema presents with worsening dyspnea and left neck mass; also found to
have left thyroid lesion and numerous bilateral pulmonary nodules. Patient died of disease 12/2007.
Pathology: TCV PTC with extrathyroidal extension, extensive necrosis, and two de-differentiated
foci (anaplastic carcinoma); þLVI.
4 51/F Left thyroid mass discovered incidentally during evaluation for hypercalcemia and parathyroid
adenoma; status post-thyroidectomy and radioactive iodine.
Pathology: Anaplastic SCSC arising from TCV PTC, with extrathyroidal extension, þPNI.
5 78/M Primary MD noted a thyroid nodule during evaluation/treatment for a parathyroid adenoma.
Pathology: Anaplastic SCSC (25% of tumor) arising from TCV PTC, with extensive necrosis; þLVI.
6 59/F Presents with thyroid mass.
Pathology: TCV PTC and areas of anaplastic transformation, extensively involving skeletal muscle
and adipose tissue; þLVI.
13 54/M Presents with a right thyroid mass compressing the trachea.
Pathology: PTC, TCV and follicular variant, and anaplastic transformation (spindle and squamoid
features), with extensive extrathyroidal spread into the trachea, lymphatics, skeletal muscle, þPNI.
14 63/F Presents with pain and an enlarging thyroid mass over 2–3 months.
Pathology: TCV PTC with anaplastic transformation.
16 56/F Presents with a thyroid mass and tracheal compression.
Pathology: Anaplastic SCSC arising from TCV PTC, with extrathyroidal extension.
18 54/M Presents with thyroid mass.
Pathology: Anaplastic SCSC arising from TCV PTC; þLVI.
19 68/F Presents with thyroid nodule.
Pathology: TCV PTC with anaplastic transformation to SCSC (<5%), with extensive extrathyroidal
extension into soft tissue and skeletal muscle, þLVI.
20 57/M Presents with thyroid nodule.
Pathology: Anaplastic SCSC arising from TCV PTC.
21 76/F Presents with thyroid mass.
Pathology: Anaplastic SCSC arising from TCV PTC, with extrathyroidal extension and invasion
of skeletal muscle.
22 74/F History of Graves’ disease status postradioactive iodine; presents with neck mass.
Pathology: TCV PTC with squamous differentiation, involving extrathyroidal soft tissue
and skeletal muscle, þLVI.
23 82/M History of Graves’ disease status postradioactive iodine (2004); presents with hoarseness
and enlarging right neck mass over 2 months.
Pathology: Anaplastic SCSC arising in association with TCV PTC, with extrathyroidal spread.
24 92/F Presents with dyspnea and hoarseness over 2 years; U/S of the neck revealed a 43.1 cm right
thyroid lobe which displaced the trachea and was associated with paralysis of the right true vocal cord.
Pathology: TCV PTC extensively infiltrative in thyroid, extrathyroidal soft tissues, þ LVI and
with transformation to anaplastic SCSC (<5%).
25 59/F History of left breast cancer status postradiation in 1999; presents 8 years later with a thyroid mass.
Pathology: SCSC arising in association with TCV PTC, with extensive extrathyroidal extension
and invasion of skeletal muscle.
26 85/F Presents with a rapidly growing thyroid mass.
Pathology: Anaplastic SCSC arising in association with TCV PTC and Warthins like variant,
with extensive extrathyoidal extension.
31 76/F Presents with shortness of breath; imaging shows a rapidly growing thyroid/laryngeal mass.
Pathology: Anaplastic SCSC arising in association with TCV PTC, with extensive necrosis,
extrathyoidal extension, extension to laryngotracheal area, and with metastases to regional
lymph nodes.
SCSC, spindle cell squamous carcinoma; TCV, tall cell variant; PTC, papillary thyroid carcinoma; LVI, lymphovascular invasion; PNI,
perineural invasion.
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Table 2. Summary of Clinical and Pathologic Findings in Anaplastic Spindle Cell Squamous Carcinoma
Arising in Patients with a History of Papillary Thyroid Carcinoma and Tall Cell Variant (Type 2)
Case Age/gender Summary of clinical and pathologic findings
3 32/F History of PTC status post-thyroidectomy, subsequent bilateral neck and paratracheal dissections.
Pathology: PTC with focal tall cell features (<10%) in 1991; multiple recurrences of TCV PTC
in lymph nodes, with development of squamoid features and solid nests, consistent with
anaplastic SCSC transformation in 2007.
9 68/F Thyroidectomy in 1979 and subsequently had multiple right neck masses and bilateral
pulmonary nodules.
Pathology: Right neck lymph nodes with metastatic TCV PTC in 1993; right neck lymph nodes in 1996
and 2001 show TCV PTC with focal anaplastic transformation and right lower lobe lung wedge in
1998 shows TCV PTC.
10 78/M Initial biopsy of thyroid mass shows TCV PTC. Presents with neck mass surrounding the carotid artery
and large veins.
Pathology: TCV PTC, invading skeletal muscle and þPNI, with more poorly differentiated areas
of tumor showing spindled appearance.
28 74/F History of a thyroid carcinoma who presents with a neck mass in 2001 and a recurrent neck mass
in 2007. In 2010, she presents with an endobronchial mass.
Pathology: Neck mass (2001) shows recurrent PTC with tall cell features; recurrent neck mass (2007)
shows a lymph node with metastatic papillary carcinoma with focal necrosis and squamous
differentiation. The endobronchial mass shows SCSC anaplastic carcinoma.
30 72/M History of papillary thyroid carcinoma in 1980 and nodal recurrence a few years later. In 1985,
he developed an ulcerating tracheal/cervical mass. Patient died of disease shortly thereafter.
Pathology: Cervical mass (1985) shows recurrent TCV PTC and anaplastic SCSC.
Table 3. Summary of Clinical and Pathologic Findings in Anaplastic Spindle Cell Squamous
Carcinoma Presenting As a Laryngeal Mass in Patients With or Without a Known History of Tall
Cell Variant Papillary Thyroid Carcinoma (Type 3)
Case Age/gender Summary of clinical and pathologic findings
7 75/F History of TCV PTC, presents with laryngeal mass.
Pathology: Recurrent TCV PTC with transition to multifocal poorly differentiated areas with squamoid
or spindle cells, consistent with anaplastic SCSC transformation.
8 74/M Presents with laryngeal mass.
Pathology: Anaplastic SCSC arising from TCV PTC, invading soft tissue between the trachea
and esophagus.
11 68/F Presents with a larynx mass.
Pathology: TCV PTC with squamous change and associated focal anaplastic carcinoma; there is
no mucosal in situ component associated with this tumor, supporting the impression that these
squamoid areas represent squamous differentiation of thyroid carcinoma, rather than a separate primary
squamous cell carcinoma of the larynx.
12 69/F History of PTC at an outside hospital in 1994; two years later presents with a left subglottic mass.
Pathology: Total laryngectomy specimen–anaplastic thyroid carcinoma with foci of TCV PTC,
extending into the muscle. The tumor is comprised of plump spindle-shaped cells with large
pleomorphic nuclei. There is no evidence of evolution from the epithelium.
15 77/M 20 pack-year smoker with history of TCV PTC in 1997; presents four years later
with a supraglottic mass.
Pathology: Total laryngectomy specimen–TCV PTC with anaplastic transformation.
17 58/M Presents with thyroid and laryngeal mass.
Pathology: Total laryngectomy specimen–Anaplastic SCSC arising from TCV PTC, replacing the
entire left lobe and isthmus of thyroid, with invasion into extrathyroidal soft tissue, skeletal muscle,
laryngeal/thyroid cartilages, and subglottic laryngeal mucosa.
27 72/F Life-long non-smoker with a history of PTC 15 years before; presents with a larynx mass.
Pathology: Anaplastic SCSC arising in association with TCV PTC, recurrent by history.
29 50/F History of TCV PTC, 5.7 cm, in 2007 with extrathyroidal extension and invasion into trachea
and cricoid cartilage with lymph node metastases with recurrence in larynx in 2009.
Pathology (2009): Anaplastic SCSC infiltrating thyroid and cricoid cartilages with areas of TCV
and lymph node metastases with TCV.
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TTF-1 reactivity in the SCSC component does support a
thyroid origin but may also be seen in other primary squa-
mous tumors, such as lung (9,10). In addition, thyroglobulin is
negative, except at the tumor edge due to diffusion artifact.
Immunohistochemistry for other markers may not be helpful
in distinguishing between a primary laryngeal squamous cell
carcinoma and SCSC. The squamous components of SCSC are
usually positive for low- and high-molecular-weight cyto-
keratins, and the spindle cells are weakly and variably posi-
tive for low-molecular-weight cytokeratins and cytokeratins
903/904 (4). In the future, molecular techniques such as dif-
ferential microRNA profiles between primary laryngeal
squamous carcinoma and anaplastic SCSC may help distin-
guish between these tumors (11–13).
Bronner and LiVolsi suggested the association of these two
unusual tumors may represent an interesting histopathologic
link in the pathology of the thyroid (4). Although several
authors subsequently have proposed a step-wise progression
from well-differentiated papillary carcinoma to poorly dif-
ferentiated carcinoma, or to anaplastic carcinoma, the patho-
genesis of this dedifferentiation is poorly understood (14–16).
The RAS mutations have been implicated in the progression
of papillary carcinoma to poorly differentiated carcinoma
(16). Recent studies have shown that BRAF is mutated at co-
don 599 in 40% ormore of PTCs (17–19). BRAFmutationsmay
be enriched in TCV PTC; one study demonstrated that all
six TCV PTC cases harbored the BRAF mutation (20). In ad-
dition, anaplastic carcinomas (two of three cases, and three of
nine cases) with adjacent TCV PTC also tested positive for the
BRAFmutation (20,21). However, BRAFmutations are seen at
all stages of PTC, including papillary microcarcinomas, indi-
cating that additional mutations must take place for dedif-
ferentiation to occur. Acquisition of p53mutationsmay be one
such event in the progression of BRAF-mutated papillary
carcinomas to anaplastic carcinoma (19).
In summary, patients found to have SCSC anaplastic car-
cinoma arising from TCV of PTC may present in various
clinical scenarios. The clinical history of TCV is very impor-
tant, especially when patients present with recurrences or
metastases that have dedifferentiation of the primary tumor.
If a patient with a history of TCV presents with a laryngeal
mass, clinicians and pathologists should consider SCSC aris-
ing from TCV PTC in the differential diagnosis, particularly if
the patient does not have a smoking history or other risk
factors for head and neck carcinogenesis.
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